Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 10/20 | 0.61 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493265 | 0.91 | ALKBH5 (0.53) | ALKBH5FTOMAPT | |
| SCHEMBL1493267 | 0.88 | ALKBH5 (0.51) | ALKBH5FTOMAPTMEN1KMT2A | |
| SCHEMBL1493371 | 0.87 | ALKBH5 (0.63) | ALKBH5FTOMAPTMEN1KMT2A | |
| SCHEMBL1493314 | 0.87 | MAPT (0.63) | ALKBH5FTOMAPTTHRBKDM4E | |
| SCHEMBL1490935 | 0.87 | ALKBH5 (0.51) | ALKBH5FTOMAPTMEN1KMT2A | |
| SCHEMBL1493335 | 0.82 | MAPT (0.45) | ALKBH5FTOMAPT | |
| SCHEMBL1493274 | 0.81 | MET (0.48) | ALKBH5FTOMAPTMEN1KMT2A | |
| SCHEMBL1493350 | 0.78 | ALKBH5 (0.44) | ALKBH5FTOMAPTKMT2A | |
| SCHEMBL28574594 | 0.77 | ALKBH5 (1.00) | ALKBH5FTOMAPT | |
| SCHEMBL1490967 | 0.75 | MAPT (0.38) | ALKBH5FTOMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ALKBH5 4874/4885FTO 4701/4885MAPT 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.